{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019011","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.660723+00:00","generated_at":"2026-06-08T03:56:31.044132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway","bullets":["Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.","Cash, cash equivalents and marketable securities $12.3M; sufficient into Q3 2024.","Phase 1 clinical trial of GT-02287 initiated in Australia; dose escalation ongoing.","Completion of single ascending dose part expected late Q4 2023/early Q1 2024; multiple ascending dose expected Q2 2024.","Preclinical data presented at Parkinson's congress showed GT-02287 reduced NfL biomarker and motor dysfunction."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019011","json":"https://secwatch.observer/filing/0001558370-23-019011.json","markdown":"https://secwatch.observer/filing/0001558370-23-019011.md","text":"https://secwatch.observer/filing/0001558370-23-019011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/0001558370-23-019011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/ganx-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:56:31.044132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"091a3e1cf3eecf1c41a72d72d770b571cb39f774","claim":"Gain Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $4.7 million, or $0.37 per share basic and diluted, EPS $0.37 per share basic and diluted.","evidence_excerpt":"On November 14, 2023, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, and business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/0001558370-23-019011-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$4.7 million, or $0.37 per share basic and diluted"},{"label":"EPS","value":"$0.37 per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}